2022
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.
Shafi S, Aung T, Xirou V, Gavrielatou N, Vathiotis I, Fernandez A, Moutafi M, Yaghoobi V, Herbst R, Liu L, Langermann S, Rimm D. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 36775354, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneityQuantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 35581307, PMCID: PMC10211373, DOI: 10.1038/s41374-022-00796-6.Peer-Reviewed Original ResearchConceptsSiglec-15 expressionNon-small cell lung cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaCancer typesOverall survivalCell carcinomaBladder cancerImmune cellsSiglec-15PD-1/PD-L1 blockadePotential future clinical trialsQuantitative immunofluorescencePD-L1 blockadeStromal immune cellsImmune checkpoint blockadeCell lung cancerFuture clinical trialsNew potential targetsCheckpoint blockadePD-L1Lung cancerClinical trialsIntra-tumoral heterogeneity
2015
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal Of Clinical Investigation 2015, 126: 169-180. PMID: 26619122, PMCID: PMC4701554, DOI: 10.1172/jci82066.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellDasatinibDiscoidin Domain ReceptorsFemaleHead and Neck NeoplasmsHumansInositol 1,4,5-Trisphosphate ReceptorsLymphatic MetastasisMaleMiddle AgedMutationNeoplasm Recurrence, LocalReceptor Protein-Tyrosine KinasesReceptors, MitogenSquamous Cell Carcinoma of Head and NeckConceptsDiscoidin domain receptor tyrosine kinase 2Neck squamous cell carcinomaSquamous cell carcinomaRecurrent tumorsWhole-exome sequencingSynchronous lymphCell carcinomaPrimary tumorDDR2 mutationsTumor pairsSrc family kinase inhibitorRecurrent/metastatic HNSCCPrimary index tumorSynchronous nodal metastasesHalf of patientsReceptor tyrosine kinase 2Tyrosine kinase 2American Cancer SocietyIndex primary tumorPotential therapeutic targetPrecision medicine approachLong-term survivalRespective primary tumorsSomatic nucleotide variantsNational Cancer Institute
2012
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.
Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.Peer-Reviewed Original ResearchSquamous cell carcinomaOP cancerOverall survivalHuman papillomavirusOral cavityAJCC stagePrognostic significanceCell carcinomaStage IFrequency of HPVNeck squamous cell carcinomaCurrent AJCC systemEnd Results registryKaplan-Meier methodEpidemiology of headL. PatientsPrognostic impactAJCC stagingOropharyngeal cancerPrognostic factorsStage IVBSurveillance EpidemiologyAJCC systemPatient populationClinical behaviorInfluence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.
Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.Peer-Reviewed Original ResearchPoor prognostic factorSquamous cell carcinomaExtracapsular extensionOral cavityOverall survivalPrognostic factorsCell carcinomaIndependent poor prognostic factorNeck squamous cell carcinomaCox proportional hazards modelSignificant OS differenceSquamous cell cancerProportional hazards modelPrognostic impactSurveillance EpidemiologyCell cancerPoor outcomeKaplan-MeierECE statusOS differenceAJCC manualEligibility criteriaHazards modelPrimary siteSurvival curves
2002
Novel therapeutics for head and neck cancer
Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Current Opinion In Oncology 2002, 14: 334-342. PMID: 11981281, DOI: 10.1097/00001622-200205000-00014.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaNeck cancerSurvival rateCell carcinomaLeading causeEpidermal growth factor receptor blockersAnti-epidermal growth factor receptor monoclonal antibodyNeck squamous cell carcinoma (HNSCC) patientsSquamous cell carcinoma patientsEpidermal growth factor receptor monoclonal antibodiesLong-term survival ratesGrowth factor receptor blockersNovel biologic agentsCell carcinoma patientsMedian survival rateReceptor monoclonal antibodyChemotherapy of headSixth leading causeCancer-related deathFifth leading causeTyrosine kinase inhibitorsFarnesyl transferase inhibitorsProcess of tumorigenesisReceptor blockers